In short
Clinical trials investigating Ziprasidone are studying its role in people with schizophrenia and related psychotic disorders. These studies look at how well it works, especially for symptoms and cognitive problems, and what outcomes change over time in different patient groups.
Key points
- Clinical trials investigating Ziprasidone are focused on people with schizophrenia and related psychotic disorders. One Phase 4 study includes people with a recent diagnosis of schizophrenia and looks at cognitive functioning using BACS App scores. Another Phase 3 study includes people with schizophrenia, schizoaffective disorder, or schizophreniform disorder who had a first-time treatment failure, and it measures symptom severity with the PANSS score. In both trials, Ziprasidone is one of several treatment options being studied. The trials are authorised and involve different patient groups and research goals. One study has 37 participants, and the other has 418 participants.
Trial overview
The trial data show two authorised interventional studies that include Ziprasidone among the treatments being examined. One study is a Phase 4 trial in people with a recent diagnosis of schizophrenia and schizophrenia spectrum disorders, and the other is a Phase 3 trial in people with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
Who is studied
The Phase 4 study includes people with a recent diagnosis of schizophrenia, which means the illness was identified not long before the trial. The Phase 3 study includes people who had a first-time treatment failure on their first-line treatment, so it focuses on patients whose first treatment did not work well enough.
The conditions listed across the trials are schizophrenia, schizophrenia spectrum disorders, schizoaffective disorder, and schizophreniform disorder. These are related mental health conditions that can involve psychosis, which means a person may have trouble telling what is real and what is not.
What is measured
One main outcome is cognitive functioning, which means thinking skills such as memory, attention, and problem-solving. This is measured with the BACS App score, and the study looks at change from baseline, meaning the difference from the starting point to later visits.
The other main outcome is symptom severity, measured with the PANSS total score, which is a standard scale used to track symptoms of psychosis. The Phase 3 study compares the mean change from baseline to six weeks between early-intensified pharmacological treatment and treatment as usual.
The Phase 4 study also lists time points at baseline, week 24, week 26, and week 50, showing that it follows participants over time to see whether scores change.
Trial phases and status
Both studies are marked Authorised, which means they have approval to be conducted. The first study is Phase 4 and has 37 participants, while the second is Phase 3 and has 418 participants.
Phase 3 studies usually compare treatments in larger groups to understand how well they work, while Phase 4 studies look at an already authorised treatment in a new or specific setting.
Treatment comparisons
In these studies, Ziprasidone is one of several drugs listed, not the only treatment being tested. The first trial lists many oral drugs, including quetiapine, risperidone, olanzapine, aripiprazole, and others, alongside Ziprasidone. The second trial also lists several oral and one intramuscular treatment option, including haloperidol, clozapine, lurasidone, and others, alongside Ziprasidone.
This means the research is looking at treatment strategies in real clinical settings, where several antipsychotic medicines may be considered. The trial summaries do not give detailed results, so the main focus is on study design and what the researchers want to measure.
What these studies may mean for patients
For patients, these trials show that Ziprasidone is being studied in people with early or treatment-resistant forms of schizophrenia-related illness. The studies are not just looking at symptom control, but also at thinking skills and how treatment changes over time. Because the trials include different patient groups, the findings may help researchers understand where Ziprasidone fits within broader treatment plans for psychotic disorders.